JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journalyesterday

    [$$] Drugmaker Raises Price of Sleep Aid Over 800%

    A small Colorado drugmaker recently raised the price for a spray form of sleep aid Ambien by as much as 843%, the latest example of how some firms are increasing prices despite mounting pressure. The median price increase is 8%, but some specific increases have been far greater. Inc. raised the list price of a 7.7 milliliter bottle of its sleep aid Zolpimist to $659 from $69.88, while increasing the price of a 4.5 milliliter bottle by 747% to $329.50, according to RELX PLC’s Elsevier Gold Standard Drug Database.

  • TheStreet.com2 days ago

    Jim Cramer: This Market Isn't Done Going Higher

    We aren't done moving higher even with the president ready to strike at a moment's notice against any of our allies.

  • Why Johnson & Johnson, Cisco Systems, and Ingredion Slumped Today
    Motley Fool2 days ago

    Why Johnson & Johnson, Cisco Systems, and Ingredion Slumped Today

    From a multibillion-dollar verdict to disappointing quarterly results and new competitive threats, these three companies lagged the broader market today.

  • Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict
    Bloomberg2 days ago

    Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict

    Johnson & Johnson should ready itself for a flood of new lawsuits after a jury ordered the company to pay $4.69 billion to 22 women who blamed their ovarian cancer on asbestos in its talc products, legal ...

  • Associated Press2 days ago

    Wells Fargo and AT&T slide while Walmart and Terex climb

    Stocks that moved substantially or traded heavily on Friday: Wells Fargo & Co., down 67 cents to $55.36 The bank's profit disappointed investors as a scandal over fraudulent accounts continued to affect ...

  • Associated Press2 days ago

    Correction: Talc Powder-Cancer Lawsuit story

    ST. LOUIS (AP) — In a story on July 12 about a jury ruling on claims that asbestos in Johnson & Johnson talcum powder contributed to ovarian cancer, The Associated Press erroneously reported that the case was the first against the company that focused on asbestos in the powder. Other lawsuits have alleged asbestos in the powder contributed to cancer.

  • Reuters2 days ago

    US STOCKS-S&P 500 at five-month high, but banks weigh after results

    U.S. stocks rose slightly on Friday, putting the S&P 500 at its highest closing level in more than five months, as gains in industrials and other areas offset a drop in financials after results from three of the big banks mostly disappointed. The industrial sector gained 0.6 percent, with Boeing Co, Caterpillar Inc and 3M Co all rose in the absence of any trade rhetoric overnight.

  • J&J vows to overturn $4.7 billion talc verdict but experts see hurdles
    Reuters2 days ago

    J&J vows to overturn $4.7 billion talc verdict but experts see hurdles

    Johnson & Johnson (JNJ.N) has vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company's products gave them ovarian cancer by arguing the plaintiffs' science was flawed and the case should not have been heard in Missouri. John Beisner, a lawyer for Johnson & Johnson, said, "One of the hardest things will be prioritising what to appeal first." He described to Reuters the company's jurisdictional and scientific arguments for overturning Thursday's verdict. In a statement responding to the verdict, J&J reiterated its position that its products never contained asbestos and were not carcinogenic.

  • Despite some wobbles, stocks end the week with more gains
    Associated Press2 days ago

    Despite some wobbles, stocks end the week with more gains

    NEW YORK (AP) — Stocks wrapped up another solid week Friday as industrial and energy companies ticked higher, but corporate earnings got off to a sluggish start as reports from several major U.S. banks failed to excite investors.

  • J&J vows to overturn $4.7 billion talc verdict but experts see hurdles
    Reuters2 days ago

    J&J vows to overturn $4.7 billion talc verdict but experts see hurdles

    Johnson & Johnson has vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company's products gave them ovarian cancer by arguing the plaintiffs' science was flawed and the case should not have been heard in Missouri. John Beisner, a lawyer for Johnson & Johnson, said, "One of the hardest things will be prioritizing what to appeal first." He described to Reuters the company's jurisdictional and scientific arguments for overturning Thursday's verdict. In a statement responding to the verdict, J&J reiterated its position that its products never contained asbestos and were not carcinogenic.

  • TheStreet.com2 days ago

    Stocks End Slightly Higher; Indexes Post Gains For Week

    Stocks closed modestly higher Friday with the Dow ending just above 25,000 and the S&P 500 just above 2,800.

  • Novartis Looks to Exit Antibacterial, Antiviral Program
    Zacks2 days ago

    Novartis Looks to Exit Antibacterial, Antiviral Program

    Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

  • InvestorPlace2 days ago

    The Johnson & Johnson Talc Lawsuit Isn’t Over Yet

    Johnson & Johnson (NYSE:JNJ) is on the hook for $4.7 billion after a Missouri court determined its talcum powder caused ovarian cancer in 22 women. Bolstering those odds of a successful appeal from Johnson and Johnson is a lot of inconclusive science about the connection between talc and ovarian cancer. The question at hand, of course, is whether or not talc causes cancer.

  • Johnson & Johnson’s Q2 2018 Earnings Estimates
    Market Realist2 days ago

    Johnson & Johnson’s Q2 2018 Earnings Estimates

    As per Wall Street analysts estimates, Johnson & Johnson (JNJ) is expected to report adjusted EPS (earnings per share) of $2.07 in the second quarter of fiscal 2018, representing YoY growth of ~12.9%. This growth compares to the company’s Q1 2018 adjusted EPS of $2.06.

  • Johnson & Johnson: The Word on Wall Street ahead of Q2 Earnings
    Market Realist2 days ago

    Johnson & Johnson: The Word on Wall Street ahead of Q2 Earnings

    Johnson & Johnson: Investor Updates ahead of Q2 2018 EarningsAnalysts’ views on Johnson & Johnson

  • Will Johnson & Johnson Meet Sales Estimates for Q2 2018?
    Market Realist2 days ago

    Will Johnson & Johnson Meet Sales Estimates for Q2 2018?

    As per Wall Street estimates, Johnson & Johnson (JNJ) will be announcing its Q2 2018 earnings results on July 17. The estimate represents year-over-year sales growth of ~8%. In Q1 2018, Johnson & Johnson had registered sales of $20 billion.

  • Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug
    Bloomberg2 days ago

    Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug

    Bayer AG and Johnson & Johnson won a judge’s ruling that upheld the validity of a patent on the blood-thinning drug Xarelto and will keep Mylan NV from selling a generic, low-cost version until August 2024, when the patent expires. Mylan NV and Sigmapharm Laboratories LLC failed to prove the patent shouldn’t have been issued, U.S. District Court Judge Lawrence Stengel in Wilmington, Delaware, said. The companies can’t sell their generic versions of the drug until the patent expires, the judge said in a separate order.

  • J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit
    Zacks2 days ago

    J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit

    Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • J&J's $4.69 Billion Talc Verdict May Open Floodgates to Suits
    Bloomberg2 days ago

    J&J's $4.69 Billion Talc Verdict May Open Floodgates to Suits

    Johnson & Johnson should ready itself for a flood of new lawsuits after a jury ordered the company to pay $4.69 billion to 22 women who blamed their ovarian cancer on asbestos in its talc products, legal experts said. There are already more than 9,000 suits claiming talc-based baby powder causes ovarian and asbestos-specific cancers. It’s not just because of the size of the award -- the biggest of 2018 and the sixth-largest product-defect verdict in U.S. history -- but the evidence that was presented at trial: internal documents that show company officials were aware for more than 30 years there were at least trace amounts of asbestos found in different batches of the talc used in its baby powder.

  • Johnson & Johnson Ordered to Pay $4.69 Billion in Cancer Case
    GoBankingRates2 days ago

    Johnson & Johnson Ordered to Pay $4.69 Billion in Cancer Case

    This is the sixth-largest product-defect award in U.S. history.

  • Johnson & Johnson still battling thousands of cases involving its baby powder
    CBS News Videos2 days ago

    Johnson & Johnson still battling thousands of cases involving its baby powder

    A jury has awarded nearly $4.7 billion in damages to a group of women who said Johnson & Johnson talcum products caused them to develop ovarian cancer. But the company is still facing thousands of cases involving its baby powder. CBS News national correspondent Jericka Duncan reports.

  • Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict
    Bloomberg Video2 days ago

    Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict

    Jul.13 -- Johnson & Johnson should ready itself for a flood of new lawsuits after a jury ordered the company to pay $4.69 billion to 22 women who blamed their ovarian cancer on asbestos in its talc products, legal experts said. Bloomberg's Max Nisen has more on "What'd You Miss?"

  • J&J to pay $4.7 bln in cancer case
    Reuters Videos2 days ago

    J&J to pay $4.7 bln in cancer case

    A Missouri jury ordered Johnson & Johnson to pay a record $4.7 billion to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer. Fred Katayama reports.

  • Johnson & Johnson ordered to pay $4.7 billion in talcum p...
    CNBC Videos2 days ago

    Johnson & Johnson ordered to pay $4.7 billion in talcum p...

    A St. Louis jury on Thursday found Johnson & Johnson liable and ordered them to pay over $4.5 billion to 22 women who claimed the company's baby powder gave them cancer. Vamil Divan, Credit Suisse, explains what that could mean for they company's stock...

  • Jury Awards Nearly $4.7 Billion In Powder Case
    Associated Press Videos2 days ago

    Jury Awards Nearly $4.7 Billion In Powder Case

    A St. Louis jury awarded nearly $4.7 billion in total damages to 22 women and their families after they claimed asbestos in Johnson & Johnson talcum powder contributed to their ovarian cancer. (July 13)